INCB123667: Clinical Trials

4 recruiting, 2 completed, 1 not yet recruiting. 4 Phase 1, 2 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 2, Recruiting 2
Phase 3	2	Not yet recruiting 1, Recruiting 1
Phase 2	1	Recruiting 1

Follow INCB123667: new trials by email Literature Review of INCB123667 trials Research Report on INCB123667

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer	Phase 3	Not yet recruiting	Incyte Corporation	590	2026-12-01	2026-10-02
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease INCB123667 - Renal Impairment	Phase 1	Recruiting	Incyte Corporation	16	2026-05-29	2026-06-16
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment INCB123667 - Hepatic Insufficiency, Liver Diseases	Phase 1	Recruiting	Incyte Corporation	16	2026-05-27	2026-06-16
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression INCB123667, Investigator's choice of chemotherapy - Ovarian Cancer	Phase 3	Recruiting	Incyte Corporation	466	2025-12-09	2026-10-15
Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants INCB123667 - Healthy Participants	Phase 1	Completed	Incyte Corporation	9	2025-11-13	2026-01-07
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression INCB123667 - Ovarian Cancer	Phase 2	Recruiting	Incyte Corporation	160	2025-11-12	2026-09-15
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants INCB123667, itraconazole, carbamazepine - Healthy Participants	Phase 1	Completed	Incyte Corporation	51	2025-05-05	2026-06-15

Conditions studied

Ovarian Neoplasms (3)  ·  Hepatic Insufficiency (1)  ·  Kidney Failure, Chronic (1)  ·  Liver Diseases (1)  ·  Lymphoma, Follicular (1)  ·  Renal Insufficiency (1)

Sponsors

Incyte Corporation (7)

Countries

United States (6)  ·  Australia (2)  ·  Belgium (2)  ·  Japan (2)  ·  Puerto Rico (2)  ·  Spain (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Ireland (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)

NIH funding

2025 (2)